Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruiji Aolunsai (JWCAR029) in adults with relapsed/refractory large B-cell lymphoma
CTR20242555Phase 2Completed
- Sponsor
- WuXi AppTec
- Start
- Sep 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of relmacabtagene autoleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by WuXi AppTec. Started Sep 2024; status: completed.
02
Drugs
relmacabtagene autoleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20242555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242555.